Sector News

AstraZeneca spends £23m on gene research tie-up with German biotech

August 23, 2017
Life sciences

AstraZeneca has invested €25m (£23m) into gene messenger drug development, through a research tie-up with German biotech Ethris.

The FTSE 100 drugmaker has agreed to pay Munich-based Ethris the sum upfront, with further payments and royalties possible depending on development progress.

Ethris, which was founded by two German scientists in 2009, specialises in RNA drugs, which instruct human cells to produce therapeutic proteins.

The alliance with AstraZeneca and its biotech division MedImmune will focus on asthma and other respiratory diseases.

Scientists believe the RNA approach holds potential to treat a range of conditions, including cancer and heart disease.

It is not AstraZeneca’s first investment in the field. Last year the company invested a further $140m (£109m) in RNA specialist Moderna Therapeutics, upping its stake to 9pc.

AstraZeneca is looking to bounce back after a negative readout from its lung cancer drugs trial Mystic last month led to its biggest single day share price fall, wiping £10bn from the company’s market value.

By Iain Withers

Source: Telegraph

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).